Credit Suisse takes sizeable stake in Real Energy

Published 06-JUL-2017 12:48 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Less than a fortnight after Real Energy (ASX: RLE) informed the market that it was witnessing a stronger and faster build-up of pressure and more gas flowing to surface from its Tamarama-1 well located in the Cooper Basin of Queensland, prominent institutional investment house, Credit Suisse Holdings (Australia) Limited has emerged as a substantial shareholder with a stake of just over 5%.

The substantial shareholder notice was released by RLE on Thursday morning. However, the bulk of Credit Suisse’s share purchase was completed in mid-June at a price of 8 cents per share. This compares with Wednesday’s closing price of 8.2 cents.

Of course share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Wednesday’s closing price represents a retracement from levels of circa 9.5 cents that the company traded at after releasing the announcement regarding Tamarama-1. Unfortunately for RLE, the news broke the day before the plunge in the oil price.

This resulted in the S&P/ASX 200 Energy (XEJ) index plummeting from 8859 points to 8499 points, a seven month low. Not surprisingly, the share prices of smaller players in the sector were hit harder than those in the ASX 200.

Credit Suisse likely sees material upside from exploration and commercialisation

Once again, today’s news coincides with a steep overnight fall in the oil price. However, the key takeaway is that Credit Suisse must see medium to long-term upside in the stock.

As finfeed.com pointed out in mid-June, RLE controls nearly 5000 square kilometres of highly prospective territory in the Cooper Basin with an established maiden 3C gas resource of 672 billion cubic feet from two discoveries, Tamarama-1 and Queenscliff-1.

Real energy cooper eromanga basin

It would appear that Credit Suisse may be focusing on the prospect of upcoming gas sales agreements with RLE’s Managing Director, Scott Brown recently saying “Gas sales agreements are likely as we begin the commercialisation of the Windorah Gas Project, and our company hopes to be a key part of the broader gas supply solution that delivers certainty and dependable energy supply to Australian industry”.

FinFeed noted in June that any news regarding gas sales agreements should on balance be a share price catalyst, particularly given the fact that some analysts see the stock as significantly undervalued.

Hunter Capital Advisors initiated coverage of the stock in May, saying, “As the company matures its 2C resource into reserves, we believe the stock will rerate with its valuation increasing to 52 cents per share on a 50% risk weighting”.

The broker currently values RLE’s 3C resource alone at 38 cents per share and expects significant share price accretion as the company builds on this resource.

As highlighted in the FinFeed article, and supported by the following projections out to 2036, the supply/demand dynamics for Cooper Basin gas, particularly in terms of supplying Queensland’s eastern seaboard hubs should work in RLE’s favour.

Natural gas demand in South east australia



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X